Lipid-lowering agents (Artovastatin)
PreclinicalSmall molecule
Lipid-lowering agents (Artovastatin) is one of 16 small molecule programs targeting Dermatomyositis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Dermatomyositis
#DrugCompanyPhaseTrials
1Xeljanz
PPrism Pharmaceuticals
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Olumiant
Eli LillyPhase 3
Jakafi
IncytePhase 2
Interleukin 2
EEssen Biotech
Phase 3
Empasiprubart
ArgenxPhase 2
Emapalumab
SSwedish Orphan Biovitrum
Phase 2
NM8074
NNovelMed Therapeutics
Phase 2
KYV-101
KKyverna Therapeutics
Phase 1
GLPG3667
GGalapagos NV
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Sao Paulo